Литература

1. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G. et al. Double-blind randomized controlled trial of monoclonal antibody human tumor necrosis factor in treatment of septic shock. Lancet 1998; 351: 929-33.

2. Abraham E, Glauser M.P, Butler T, Gabrino J, Gelmont D. et al. p55 tumor necro­sis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled mulcenter trial. JAMA 1997; 277: 1531-8.

3. Albertson T.E, Panacek E.A, MacArthur R.D, Johnson S.B. et al. Multicenter eval­uation pf a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis. Crit Care Med 2003; 31: 419-27.

4. Alejandria M.M, Lansang M.A, Dans L.F, Mantaring J.B.V. Intravenous immunoglobulin for treating sepsis and septic shock (Cochrane review). The Cochrane Library 2002; issue 4. Oxford: Update Software.

5. Annane D, Sebille V, Charpentier C, Bollaert P.E, Fraciois B. et al. Effect of treat­ment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-71.

6. Arndt P, Abraham E. Immunological therapy of sepsis: experimental therapies. Int Care Med 2001; 27:5104-115.

7. Arons M.M, Wheeler A.P, Bernard G.R, Christman B.W, Russell J.A. et al. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Crit Care Med 1999; 27:699-707.

8. Bernard G.R, Wheeler A.P, Russell J.A, Schein R, Summer W.R. et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Eng J Med 1997; 336: 912-8.

9. Bochud P.Y, Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 2003; 326:262-6.

10. Bone R.C, Balk R.A, Fein A.M, Perl T.M, Wenzel R.P. et al. A second large con­trolled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23: 994-1006.

11. Carle J. Immunological therapy in sepsis: currently available. Int Care Med 2001; 27:893-103.

12. Carvalho PR.A, Trotta E.A. Advances in sepsis diagnosis and treatment. J de Pediatria 2003; 79 Suppl 2: S195-204.

13. Cronin L, Cook D.J, Carlet J. Corticosteroid treatment for sepsis: a critical apraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430-9.

14. Dhainaut J.F.A, Tenaillon A, Hemmler M, Damas P, Le Tulzo Y. et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, place­bo-controlled, multicenter trial. Crit Care Med 1998; 26: 1963-71.

15. Pagan E.A, Singer M. Immunoterapy in the management of sepsis. Posgrad Med 1995;71:71-8.

16. Friedrich I, Silber R.E, Bauman B, Fischer C, Holzheimer R.G. IgM-enriched immunoglobulin preparation for immunoprophylaxis in cardiac surgery. Eur J Med Res 2002 dec 17; 7 (12): 544-9.

17. Fujiwara T. et al. Effect of immunoglobulin therapy on polymorphonuclear leuco­cytes in whole blood of neonates. Clin Exp Immunol 1997; 107: 435-9.

18. Glauser M.P. Pathophysiology basis of sepsis: considerations for future strategies of intervention. Crit Care Med 2000; 28 Suppl: 4-8.

19. Haque K.N. et al. Comparsion of two types of intravenous immunoglobulins in the treatment of neonatal sepsis. Clin Exp Immunol 1995; 101: 328-33.

20. Hoffmann J.N, Vollmar B, Laschke M.W, Inthorn D, Kaneider N.C. et al. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Hemost 2002; 88: 242-52.

21. HotchkissR.S, Karl I.E. The pathophysiology and treatment of sepsis. N Eng J Med 2003; 348: 138-50.

22. Ken D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O. et al. Immunologic and hemodynamic effects of rlow dose" hyrdrocortisone in septic shock. Am J Resp Crit Care Med 2003; 167: 512-20.

23. Lauterbach R, Pawlik D, Kowalczyk D, Ksycinski W, Helwich E. et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med 1999; 27: 807-14.

24. Melero J. et al. Human polyreactive IgM monoclonal antibodies with bloking activ­ity against self-reactive IgG. Scand J Immunol 1997; 45: 393-400.

25. Messori A, Vacca F, Vaiani M, Tripoli! S. Antitrombin III in patients admitted to intensive care units: a multicentre observational study. Crit Care Med 2002; 6: 447-51.

26. Mohr M. et al. Effect of early treatment with immunoglobulin on critical illness polyneuropathy following MOF and gram-negative sepsis. Int Care Med 1997; 23: 1144-49.

27. Opal S.M, Fisher C.J, Dhainaut J.F.A, Vincent J.L, Brase R. et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25: 1115-24.

28. Poynton C.H. et al. Use of IgM-enriched intravenous immunoglobulin (Pentaglobin") in bone marrow transplantation. Bone Marrow Transpl 1992; 9: 451-7.

29. Rinaldi M. et al. Effectiveness of immunoglobulins for the prevention of sistemic infections. Clin Drug Invest 1995; 10: 328-36.

30. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A. et al. Early goal-directed ther­apy in the treatment of severe sepsis and septic shock. N Eng J Med 2001; 345: 1368-77.

31. Roemisch J, Gray E, Hoffmann J.N, Wiedermann C.J. Antitrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolisis 2002; 13:657-70.

32. Rott R.K, Lodato R.F, Patrick W, Cade J.F, Milwee S. et al. Pneumonia Sepsis Study Group Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 31: 367-73.

33. Saez-Llorens X, McCracen G.H. Sepsis syndrome and septic shock in pediatrics: current concepts of terminology, pathophysiology, and management. J Pediatr 1993; 123: 497-508.

34. The ARDS network. Ketokonazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2000' 283-1995-2002. ' '

35. Tugrul S, Ozcan P.E, Akinci O.Seyhun Y, Cagatay A.et al. The effects of IgM-enriched immunoglobulin preparation in pacients with severe sepsis Crit Care 2002; 6: 357-62.

36. Vincent J.L, Abraham E, Annane D, Bernard G, Rivers E, Van den Berghe G. Reducing mortality in sepsis: new directions. Crit Care 2002; 6 Suppl 3: 1-18.

37. Warren B.L, Eid A, Singer P, Pillay S.S, Carl P. et al. Caring for the critically ill patient. High-dose antitrombin III in severe sepsis: a randomized controled trial JAMA 2001; 286: 1869-78.

38. Wolf H.M, Eibl M.M. Immunomodulatory effect of immunoglobulins Clin Exp Rheumatol 1996; 14: Suppl 15 S17-25.

39. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassesment. Crit Care Med 1997; 25:1095-1100.